Medications for Nonradiographic Axial Spondyloarthritis

5 results

  • bimzelx

    (bimekizumab)
    UCB, Inc.
    BIMZELX is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.

  • cimzia

    (certolizumab pegol)
    UCB, Inc.
    CIMZIA is indicated for treating moderately to severely active Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 and older, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults.

  • cosentyx

    (secukinumab)
    Novartis Pharmaceuticals Corporation
    COSENTYX is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis from age 2, adult ankylosing spondylitis, active non-radiographic axial spondyloarthritis, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.

  • rinvoq

    (Upadacitinib)
    AbbVie Inc.
    RINVOQ is indicated for adults and pediatric patients (2+) with various conditions, including moderately to severely active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, after inadequate response to TNF blockers.

  • taltz

    (ixekizumab)
    Eli Lilly and Company
    TALTZ is indicated for the treatment of moderate-to-severe plaque psoriasis in patients aged 6 and older, as well as for adults with active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.